Abstract
Gastroduodenal mucosal damage was endoscopically compared between aceclofenac, a non-steroidal anti-inflammatory drug, and sodium diclofenac or placebo in a double-blind clinical trial. Thirty healthy male volunteers received 150 mg/ day of aceclofenac, 75 mg/day of sodium diclofenac or placebo for 2 weeks. Aceclofenac caused significantly less gastropathy than sodium diclofenac, and placebo caused no gastropathy. Both the gastric mucosal hexosamine content and gastroduodenal blood flow were significantly reduced by sodium diclofenac, while gastric mucosal hexosamine was significantly increased and gastroduodenal blood flow was unchanged with aceclofenac. Aceclofenac appears to have a low potential for causing gastroduodenal mucosal damage in humans.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
